Decreasing the intracellular level of .beta.-catenin by administering hydroxymatairesinol
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 7, 2001
Grant Date -
N/A
app pub date -
Apr 17, 2000
filing date -
Apr 17, 2000
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention relates to a method for decreasing the intracellular, especially nuclear level of .beta.-catenin in an individual and to a method for the prevention or treatment of a disease or condition in an individual, wherein said disease or condition is related to a mutant APC gene or to an elevated level of intracellular .beta.-catenin. Furthermore, the invention relates to methods for screening a subject to determine if said subject is a carrier of a mutant APC gene, and to methods for diagnosing an individual's predisposition for a disease or condition in an individual, said disease or condition being related to a mutant APC gene or to an elevated level of intracellular .beta.-catenin.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully